Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): A feasibility study

Experimental and Molecular Pathology

Volumn 98, Issue 1, 2015, Pages 113-118

  Zwaenepoel, Karen ^a   Merkle, Dennis ^b   Cabillic, Florian ^c   Berg, Erica ^d   Belaud Rotureau, Marc Antoine ^c   Grazioli, Vittorio ^e   Herelle, Olga ^f   Hummel, Michael ^d   Le Calve, Michele ^c   Lenze, Dido ^d   Mende, Stefanie ^d   Pauwels, Patrick ^a   Quilichini, Benoit ^g   Repetti, Elena ^e  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b ABBOTT GMBH AND CO KG   (Germany)

^c UNIVERSITÉ DE RENNES 1   (France)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Italian Diagnostic Center   (Italy)

^f Abbott   (France)

^g Biomnis Laboratory Laboratory of Cytogenetics   (France)

Author keywords

ALK; Automation; BioView; FISH; Fluorescence in situ hybridization; VP 2000

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ALK GENE; ARTICLE; CLINICAL ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; ENZYME ASSAY; FEASIBILITY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FLUOROSCOPY; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; LABORATORY AUTOMATION; NON SMALL CELL LUNG CANCER; REPRODUCIBILITY; SYSTEM ANALYSIS; WORKFLOW; ALGORITHM; AUTOMATION; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER PROGRAM; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; PROGNOSIS; STATISTICAL ANALYSIS;

ALGORITHMS; AUTOMATION; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DATA INTERPRETATION, STATISTICAL; FEASIBILITY STUDIES; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SOFTWARE;

EID: 84922657096     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.01.005     Document Type: Article

References (22)

1. Abel H.J., Al-Kateb H., Cottrell C.E., Bredemeyer A.J., Pritchard C.C., Grossmann A.H., Wallander M.L., Pfeifer J.D., Lockwood C.M., Duncavage E.J. Detection of gene rearrangements in targeted clinical next-generation sequencing. J. Mol. Diagn. 2014, 16:405-417.
2. Bronte G., Rolfo C., Giovannetti E., Cicero G., Pauwels P., Passiglia F., Castiglia M., Rizzo S., Vullo F.L., Fiorentino E., Van Meerbeeck J., Russo A. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit. Rev. Oncol. Hematol. 2014, 89:300-313.
3. Cabillic F., Gros A., Dugay F., Begueret H., Mesturoux L., Chiforeanu D.C., Dufrenot L., Jauffret V., Dachary D., Corre R., Lespagnol A., Soler G., Dagher J., Catros V., Le Calve M., Merlio J.P., Belaud-Rotureau M.A. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J. Thorac. Oncol. 2014, 9:295-306.
4. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., Riely G.J., Solomon B., Ou S.H., Kim D.W., Salgia R., Fidias P., Engelman J.A., Gandhi L., Jänne P.A., Costa D.B., Shapiro G.I., Lorusso P., Ruffner K., Stephenson P., Tang Y., Wilner K., Clark J.W., Shaw A.T. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012, 13:1011-1019.
5. Chen Z., Fillmore C.M., Hammerman P.S., Kim C.F., Wong K.K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 2014, 14:535-546.
6. Gridelli C., De Marinis F., Di Maio M., Cortinovis D., Cappuzzo F., Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: review of the evidence. Lung Cancer 2011, 71:249-257.
7. Gruber K., Horn H., Kalla J., Fritz P., Rosenwald A., Kohlhäufl M., Friedel G., Schwab M., Ott G., Kalla C. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay. J. Thorac. Oncol. 2014, 9:307-315.
8. Jänne P.A., Wang X., Socinski M.A., Crawford J., Stinchcombe T.E., Gu L., Capelletti M., Edelman M.J., Villalona-Calero M.A., Kratzke R., Vokes E.E., Miller V.A. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J. Clin. Oncol. 2012, 30:2063-2069.
9. Laffert V.M., Warth A., Penzel R., Schirmacher P., Jonigk D., Kreipe H., Schildhaus H.U., Merkelbach-Bruse S., Büttner R., Reu S., Kerler R., Jung A., Kirchner T., Wölfel C., Petersen I., Rodriguez R., Jochum W., Bartsch H., Fisseler-Eckhoff A., Berg E., Lenze D., Dietel M., Hummel M. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. Lung Cancer 2013, 81:200-206.
10. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G., Jenkins R.B., Kwiatkowski D.J., Saldivar J.S., Squire J., Thunnissen E., Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Mol. Diagn. 2013, 15:415-453.
11. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I., Fujita Y., Okinaga S., Hirano H., Yoshimori K., Harada T., Ogura T., Ando M., Miyazawa H., Tanaka T., Saijo Y., Hagiwara K., Morita S., Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
12. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., Seto T., Satouchi M., Tada H., Hirashima T., Asami K., Katakami N., Takada M., Yoshioka H., Shibata K., Kudoh S., Shimizu E., Saito H., Toyooka S., Nakagawa K., Fukuoka M. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010, 11:121-128.
13. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., Palmero R., Garcia-Gomez R., Pallares C., Sanchez J.M., Porta R., Cobo M., Garrido P., Longo F., Moran T., Insa A., De Marinis F., Corre R., Bover I., Illiano A., Dansin E., de Castro J., Milella M., Reguart N., Altavilla G., Jimenez U., Provencio M., Moreno M.A., Terrasa J., Muñoz-Langa J., Valdivia J., Isla D., Domine M., Molinier O., Mazieres J., Baize N., Garcia-Campelo R., Robinet G., Rodriguez-Abreu D., Lopez-Vivanco G., Gebbia V., Ferrera-Delgado L., Bombaron P., Bernabe R., Bearz A., Artal A., Cortesi E., Rolfo C., Sanchez-Ronco M., Drozdowskyj A., Queralt C., de Aguirre I., Ramirez J.L., Sanchez J.J., Molina M.A., Taron M., Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13:239-246.
14. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., Wu Y.L., Thomas M., O'Byrne K.J., Moro-Sibilot D., Camidge D.R., Mok T., Hirsh V., Riely G.J., Iyer S., Tassell V., Polli A., Wilner K.D., Jänne P.A. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 20:2385-2394.
15. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
16. Soda M., Isobe K., Inoue A., Maemondo M., Oizumi S., Fujita Y., Gemma A., Yamashita Y., Ueno T., Takeuchi K., Choi Y.L., Miyazawa H., Tanaka T., Hagiwara K., Mano H. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin. Cancer Res. 2012, 18:5682-5689.
17. Solomon B., Wilner K.D., Shaw A.T. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin. Pharmacol. Ther. 2014, 95:15-23.
18. Tembuyser L., Tack V., Zwaenepoel K., Pauwels P., Miller K., Bubendorf L., Kerr K., Schuuring E., Thunnissen E., Dequeker E.M. The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization. PLoS One 2014, 9:e112159.
19. Thunnissen E., Bubendorf L., Dietel M., Elmberger G., Kerr K., Lopez-Rios F., Moch H., Olszewski W., Pauwels P., Penault-Llorca F., Rossi G. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012, 461:245-257.
20. Wu K., Huang R.S., House L., Cho W.C. Next-generation sequencing for lung cancer. Future Oncol. 2013, 9:1323-1336.
21. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., Zhang S., Wang J., Zhou S., Ren S., Lu S., Zhang L., Hu C., Hu C., Luo Y., Chen L., Ye M., Huang J., Zhi X., Zhang Y., Xiu Q., Ma J., Zhang L., You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12:735-742.
22. Zwaenepoel K., Van Dongen A., Lambin S., Weyn C., Pauwels P. Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements-comparison of multiple immunohistochemical methods. Histopathology 2014, 65:539-548.